TY - JOUR
T1 - Magnesium Administration in Chronic Kidney Disease
AU - Vermeulen, Emma A.
AU - Vervloet, Marc G.
N1 - Funding Information: This work was supported by the NIGRAM2+ consortium, financed by the PPP Allowance made available by Top Sector Life Sciences and Health to The Dutch Kidney Foundation (16TKI02) under Health Holland grant no. LSHM17034-HSGF to stimulate public private partnerships. Publisher Copyright: © 2023 by the authors.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - Awareness of the clinical relevance of magnesium in medicine has increased over the last years, especially for people with chronic kidney disease (CKD), due to magnesium’s role in vascular calcification and mineral metabolism. The inverse association between serum magnesium and clinically relevant, adverse outcomes is well-established in people with CKD. Subsequent intervention studies have focused on the effect of magnesium administration, mainly in relation to cardiovascular diseases, mineral bone metabolism, and other metabolic parameters. The most commonly used routes of magnesium administration are orally and by increasing dialysate magnesium. Several oral magnesium formulations are available and the daily dosage of elemental magnesium varies highly between studies, causing considerable heterogeneity. Although data are still limited, several clinical studies demonstrated that magnesium administration could improve parameters of vascular function and calcification and mineral metabolism in people with CKD. Current clinical research has shown that magnesium administration in people with CKD is safe, without concerns for severe hypermagnesemia or negative interference with bone metabolism. It should be noted that there are several ongoing magnesium intervention studies that will contribute to the increasing knowledge on the potential of magnesium administration in people with CKD.
AB - Awareness of the clinical relevance of magnesium in medicine has increased over the last years, especially for people with chronic kidney disease (CKD), due to magnesium’s role in vascular calcification and mineral metabolism. The inverse association between serum magnesium and clinically relevant, adverse outcomes is well-established in people with CKD. Subsequent intervention studies have focused on the effect of magnesium administration, mainly in relation to cardiovascular diseases, mineral bone metabolism, and other metabolic parameters. The most commonly used routes of magnesium administration are orally and by increasing dialysate magnesium. Several oral magnesium formulations are available and the daily dosage of elemental magnesium varies highly between studies, causing considerable heterogeneity. Although data are still limited, several clinical studies demonstrated that magnesium administration could improve parameters of vascular function and calcification and mineral metabolism in people with CKD. Current clinical research has shown that magnesium administration in people with CKD is safe, without concerns for severe hypermagnesemia or negative interference with bone metabolism. It should be noted that there are several ongoing magnesium intervention studies that will contribute to the increasing knowledge on the potential of magnesium administration in people with CKD.
KW - cardiovascular disease
KW - chronic kidney disease
KW - magnesium
KW - magnesium administration
KW - magnesium supplementation
UR - http://www.scopus.com/inward/record.url?scp=85147802324&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/nu15030547
DO - https://doi.org/10.3390/nu15030547
M3 - Review article
C2 - 36771254
SN - 2072-6643
VL - 15
JO - NUTRIENTS
JF - NUTRIENTS
IS - 3
M1 - 547
ER -